Lance Hoover runs the paid acquisition at Odin Stem Cells and Reju Stem Cell Clinic. When a clinic partners with RevCELL he is the one building and running the campaigns — the same person, in live accounts, finding out the week Meta changes what it will approve rather than reading about it later.
Stem cell therapy is a restricted category on both platforms, and the restriction is rarely about targeting. It is about the words — in the ad, on the page it points to, and in the testimonial underneath it.
Meta and Google both treat regenerative medicine as restricted health advertising, and the line moves without notice. Campaigns are structured so a single disapproval does not take the account down with it, and claim language is written to the current line rather than last year’s.
A $10,000 elective treatment is not an impulse buy. The creative has to earn a stranger’s attention and then survive three weeks of research and a conversation with a spouse. Lance came out of filmmaking, and the storytelling is why the campaigns convert rather than just collect clicks.
An approved ad pointed at a non-compliant page still gets the account restricted, and a compliant page that does not answer the objection still wastes the click. Both get written together, by the same people, because splitting them is how clinics end up with a good ad account and no patients.
Patients leave and come back three or four times before they book. Retargeting is built around that window instead of a seven-day default, with sequencing that assumes the reader has already seen the first ad.
Budgets, creative rotation and audience changes get made as the data arrives. The monthly report is a record of decisions already taken, not the moment decisions get taken.
Conversion tracking and CRM attribution wired so that the number in Ads Manager and the number in the clinic’s deposits agree. Without that, every optimisation afterwards is a guess with a dashboard attached.
The account is not a side project. Lance is in Odin’s and Reju’s ad accounts every day. A partner clinic gets the same hands, not a junior buyer working from a brief written by someone who has never advertised in this category.
Compliance knowledge comes from being restricted. Everything we know about what Meta will currently approve came from running live campaigns and occasionally getting it wrong in our own accounts first. That is a materially different kind of knowledge from a policy page read once.
Ads are not the whole system. Paid acquisition produces leads in the first weeks. Revenue follows the consultation calendar. If the consultation is the bottleneck, more spend makes the problem more expensive, and we will say so rather than sell you a larger budget.
The founders are in the accounts. Lance is in the ad account himself rather than briefing somebody who is. That is the reason this will never be the cheapest line on a shortlist, and the reason a change gets made the week it is needed rather than the month after.
What clinic owners ask before the first call.
Yes, within limits that are stricter than most practices expect and that change without notice. The failure mode is almost never targeting; it is claim language in the ad, on the landing page, or in a patient testimonial. We run live campaigns for regenerative medicine clinics now, which is the only reliable way to know where the line currently sits.
Enough to gather signal before the first optimisation, which in a cash-pay category with a long consideration window means thinking in months rather than weeks. The honest answer depends on your market, your treatment pricing and how much consultation capacity you have, and it is a specific number we work out on the strategy call rather than a figure to quote in the abstract.
Google captures people already looking for the treatment; Meta creates demand among people who have the condition and have never considered regenerative medicine. Most clinics need both eventually, and which one goes first depends on whether your market already searches for what you offer.
We have been through it. Campaigns are structured so one disapproval is contained rather than account-wide, appeals go out the same day, and the underlying claim language gets fixed so the same rejection does not recur. Treating a restriction as a surprise is what turns it into a lost month.
The reasoning behind the system, written out in full.
Every engagement starts from the same place: what a stem cell therapy marketing agency should actually cover.
Book a 30-minute strategy call. We will review your clinic, walk through the system end to end, and tell you plainly whether we are the right people for it.
Book Your Strategy Call